Off-label use of recombinant factor Vlla: why we need better drug monitoring

Hébert, Paul C.; Fergusson, Dean; Stanbrook, Matthew B.
January 2011
CMAJ: Canadian Medical Association Journal;1/11/2011, Vol. 183 Issue 1, p26
Academic Journal
In this article the author discusses the importance of drug monitoring regarding the off-label use of recombitant factor VIIa. According to the author, VIIa was first licensed in 1996 for the treatment and prevention of bleeding connected to surgery for people with hemophilia. He adds that drug monitoring can be done by having a better collaboration between the payer and the insurer and having health professionals participate in evidence-based evaluation of new drugs.


Related Articles

  • Haemophilia part 1 : an introduction. Khalr, Kate // British Journal of Nursing;6/13/2013, Vol. 22 Issue 11, p620 

    The author discusses haemophilia, with a focus on the disease's incidence, genetic transmission, and symptoms including severe bleeding manifestations. Topics include X-linked disorders and haemophilia A, diagnosis by blood clotting screen and factor assay, and activated partial thromboplastin...

  • Pharmacovigilance: empowering healthcare professionals and patients. Steurbaut, Stephane; Hanssens, Yolande // International Journal of Clinical Pharmacy;Oct2014, Vol. 36 Issue 5, p859 

    The European Union has thoroughly reformed its pharmacovigilance legislation in July 2012. Despite the changes, underreporting of adverse drug reactions remains a concern. This underreporting seems to be partially associated with incorrect customs and beliefs by healthcare professionals....

  • Five year outcome in patients withdrawn from long term treatment with diazepam. Holton, Anthony; Tyrer, Peter // BMJ: British Medical Journal (International Edition);5/12/90, Vol. 300 Issue 6734, p1241 

    Examines the effect of long-term treatment of diazepam on patients. Determination on the drug history of patients; Problems on patients dependence on benzadiazepines; Importance of careful monitoring in the intake of drugs.

  • Off-Label Use of Recombinant Factor VIIa. Phillips, Anne // Annals of Internal Medicine;9/6/2011, Vol. 155 Issue 5, p337 

    Two letters to the editor are presented in response to the article on the off-label use of recombinant factor VIIa (rFVIIa) in the April 19, 2011 issue. Two letters to the editor are presented in response to the article on the off-label use of recombinant factor VIIa (rFVIIa) in the April 19,...

  • Lifesaving Stopgap for Bleeders.  // Time;8/6/1965, Vol. 86 Issue 6, p66 

    The article reports on the method discovered by Stanford University physiologist Judith Graham Pool that aims to prevent hemorrhages by concentrating clot-promoting proteins for hemophilia victims. Pool reveals that frozen plasma leaves the antihemophilic globulin (AHG), which is insufficient in...

  • New hemophilia treatment approved. Key, Nigel // Hem/Onc Today;3/10/2008, Vol. 9 Issue 4, p9 

    The article reports on the U.S. Food & Drug Administration approval of Wyeth Pharmaceuticals' Xyntha, a recombinant factor VIII for the treatment of hemophilia A for the control and prevention of bleeding episodes and surgical prophylaxis. It was genetically engineered from the genes of Chinese...

  • Clozapine initiation in crisis teams. Gonzalez, Carlos; Kodimela, Kalyani; Poynton, Amanda // British Journal of Medical Practitioners;June2013, Vol. 6 Issue 2, p1 

    Aims: Our aim was to investigate the practicalities and success rate of clozapine titration in the community in a large sample of patients referred to three crisis teams in a defined geographical area. Methods: We collected data retrospectively of all the referrals for clozapine initiation to...

  • Assessment of community pharmacists concerning pharmacovigilance in Iraq. Salih, Muhannad R. M.; Abd, Arwa Y.; Kurmanji, Jaafer M.; Al-Lela, Omer Qutaiba B. // Archives of Pharmacy Practice;Oct-Dec2016, Vol. 7 Issue 4, p136 

    Objectives: This study was designed to explore the awareness and attitude of the pharmacists working in the retail pharmacies toward the national adverse drug reactions (ADRs) system activities in Iraq. Methods: A cross-sectional survey using a validated self-administered questionnaire was used...

  • Rivaroxaban being tested in patients with arrhythmia disorders in ROCKET AF trial.  // Cardiology Today;Nov2008, Vol. 11 Issue 11, p11 

    The article reports that the ROCKET AF clinical trial investigated the safety and efficacy of rivaroxaban compared to warfarin in treating patients with arrhythmia disorders in the U.S. The trial will involve at least 14,000 persons who will be randomly assigned to rivaroxaban or warfarin during...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics